The DOI matches its Crossref record; 279 of the 279 references it cites were found in a registry or an index.
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
Abstract
Warfarin anticoagulation effect is characterized by marked variability, some of which has been attributed to CYP2C9 polymorphisms. This study prospectively examines whether a priori knowledge of CYP2C9 genotype may improve warfarin therapy. Patients were randomly assigned to receive warfarin by a validated algorithm ("control", 96 patients) or CYP2C9 genotype-adjusted algorithms ("study", 95 patients). The first therapeutic international normalized ratio and stable anticoagulation were reached 2.73 and 18.1 days earlier in the study group, respectively (P<0.001). The faster rate of initial anticoagulation was driven by a 28% higher daily dose in the study group (P<0.001). Study group patients spent more time within the therapeutic range (80.4 vs 63.4%, respectively, P<0.001) and experienced less minor bleeding (3.2 vs 12.5%, P<0.02, respectively). In conclusion, CYP2C9 genotype-guided warfarin therapy is more efficient and safer than the "average-dose" protocol. Future research should focus on construction of algorithms that incorporate other polymorphisms (VKORC1), host factors, and environmental influences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–279 of 279
Polymorphism of cytochrome P450 and xenobiotic toxicity
Ingelman‐Sundberg, M. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00492-4 · Cited by 129
Kunugi, H., Nanko, S., Ueki, A., Otsuka, E., Hattori, M., Hoda, F., Vallada, H., Arranz, M. J., & Collier, D. A. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13289-4 · Cited by 128
Coughtrie, M. W. H., Gilissen, R., Benedicte, S. H. E. K., Strange, R. C., Fryer, A. A., Jones, P. W., & Bamber, D. E. (1998) · Biochemical Journal · doi:10.1042/bj3370045 · Cited by 128
Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics
Wright, S. H. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.021 · Cited by 127
Molecular cloning and expression of novel sulphotransferase-like cDNAs from human and rat brain
Falany, C. N., Xie, X., Wang, J., FERRER, J., & Falany, J. L. (2000) · Biochemical Journal · doi:10.1042/bj3460857 · Cited by 127
Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysis
Li, Y. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108674 · Cited by 127
Impact of genotype on adverse effects during treatment with metoprolol: A prospective clinical study
Fux, R., Mörike, K., Pröhmer, A. M. T., Delabar, U., Schwab, M. G., Schaeffeler, E., LORENZ, G., Gleiter, C. H., Eichelbaum, M. F., & Kivistö, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.004 · Cited by 126
Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M. G., Lütjohann, D., von Bergmann, K., Eichelbaum, M. F., & Kivistö, K. T. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200505000-00005 · Cited by 125
Andersson, T., Holmberg, J., Rohss, K. M., & Walan, A. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.t01-1-00702.x · Cited by 125
Otterness, D. M., Szumlanski, C. L., Wood, T. C., & Weinshilboum, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1004 · Cited by 125
Pharmacogenomics of the OATP and OAT Families
Marzolini, C., Tirona, R. G., & Kim, R. B. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.273.29831 · Cited by 124
Manolis, E., & Pons, G. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03484.x · Cited by 124
Genetics of red cell COMT activity: Analysis of thermal stability and family data
Spielman, R. S., Weinshilboum, R. M., & Opitz, J. M. (1981) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320100311 · Cited by 123
Campbell, N. R. C., Loon, J. A. V., & Weinshilboum, R. M. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90108-0 · Cited by 122
Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates
Yu, A., Idle, J. R., & Gonzalez, F. J. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120034000 · Cited by 122
Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
Yamazaki, H., & Shimada, T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00304-3 · Cited by 121
Her, C., Kaur, G. P., Athwal, R. S., & Weinshilboum, R. M. (1997) · Genomics · doi:10.1006/geno.1997.4683 · Cited by 116
Hirouchi, M., Suzuki, H., Itoda, M., Ozawa, S., Sawada, J.-I., Ieiri, I., Ohtsubo, K., & Sugiyama, Y. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026422.06207.33 · Cited by 110
Pharmacogenetics in Cardiovascular Antithrombotic Therapy
Marín, F. R., Gónzález‐Conejero, R., Capranzano, P., Bass, T. A., Roldán, V., & Angiolillo, D. J. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.084 · Cited by 110
Niemi, M., Arnold, K. A., Backman, J. T., Pasanen, M. K., Gödtel‐Armbrust, U., Wojnowski, L., Zanger, U. M., Neuvonen, P. J., Eichelbaum, M. F., Kivistö, K. T., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230422.50962.91 · Cited by 109
Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations
Ellis, K., Stouffer, G. A., McLeod, H. L., & Lee, C. R. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.143 · Cited by 108
Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients
Kurzawski, M., Gawronska-Szklarz, B., Wrześniewska, J., Siuda, A., Starzyñska, T., & Droździk, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0183-2 · Cited by 106
Nielsen, K. K., Flinois, J.-P., Beaune, P. H., & Brøsen, K. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13120-0 · Cited by 105
Ishizaki, T., Sohn, D., Kobayashi, K., et al. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199404000-00018 · Cited by 103
Ziegler, S., Schillinger, M., Funk, M., Felber, K., Exner, M., Mlekusch, W., Sabeti, S., Amighi, J., Minar, E., Brunner, M., et al. (2005) · Stroke · doi:10.1161/01.str.0000169922.79281.a5 · Cited by 102
haplotype structure in European American warfarin patients and association with clinical outcomes
Veenstra, D., Blough, D. K., Higashi, M. K., Farin, F. M., Srinouanprachan, S., Rieder, M. J., & Rettie, A. E. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.019 · Cited by 102
Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide
Zhang, W., He, Y., Han, C., Liu, Z., Li, Q., Fan, L., Tan, Z., Zhang, W., Yu, B., Wang, D., et al. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02686.x · Cited by 101
Palareti, G., Legnani, C., Cosmi, B., Guazzaloca, G., Cini, M., & Mattarozzi, S. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01330.x · Cited by 100
Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
Fukuda, T., Yamamoto, I., Nishida, Y., Zhou, Q., Ohno, M., Takada, K., & Azuma, J. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00913.x · Cited by 98
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Innocenti, F., Iyer, L., & Ratain, M. J. (2001) · PubMed · Cited by 98
Staritz, P., Kurz, K., Stoll, M., Giannitsis, E., Katus, H. A., & Ivandic, B. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.12.118 · Cited by 98
Ibeanu, G. C., Blaisdell, J. A., Ghanayem, B. I., et al. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00006 · Cited by 98
Meckley, L. M., Wittkowsky, A. K., Rieder, M. J., Rettie, A. E., & Veenstra, D. L. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-09-0552 · Cited by 95
Genetic Variants of the Human H+/Dipeptide Transporter PEPT2: Analysis of Haplotype Functions
Pinsonneault, J. K., Nielsen, C. U., & Sadée, W. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073098 · Cited by 95
Koyama, E., Chiba, K., Tani, M., & Ishizaki, T. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36731-x · Cited by 95
Thiopurine Methyltransferase Activity in Spain: A Study of 14,545 Patients
Gisbert, J. P., Gomollón, F., Cara, C., Luna, M., González‐Lama, Y., Pajares, J. M., Maté, J., & Guijarro, L. G. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9119-z · Cited by 95
Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea
Mehlotra, R. K., Ziats, M. N., Bockarie, M. J., & Zimmerman, P. A. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0092-9 · Cited by 94
Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer
Zhou, Q. S., Sparreboom, A., Tan, E.-H., Cheung, Y., Lee, A., Poon, D. Y. H., Lee, E. J. D., & Chowbay, B. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02330.x · Cited by 94
Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case
Tavadia, S. M. B., Mydlarski, P. R., Reis, M. D., Mittmann, N., Pinkerton, P. H., Shear, N. H., & Sauder, D. N. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.103980 · Cited by 93
Xu, G., Bhatnagar, V., Wen, G., Hamilton, B. A., Eraly, S. A., & Nigám, S. K. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00612.x · Cited by 93
Li, T., Vallada, H., Curtis, D., Arranz, M. J., Xu, K., Cai, G., Deng, H., Liu, J., Murray, R. M., Liu, X., et al. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00002 · Cited by 91
Cuisset, T., Frère, C., Quilici, J., Morange, P., Saut, N., Lambert, M., Camoin‐Jau, L., Juhan-Vague, I., Bonnet, J., & Alessi, M. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.01.012 · Cited by 91
Fujita, K., Nagata, K., Ozawa, S., Sasano, H., & Yamazoe, Y. (1997) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021846 · Cited by 90
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
Singh, A. S., Paoluzzi, L., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2072 · Cited by 90
Incidence and predictors of severe bleeding during warfarin treatment
Lindh, J. D., Holm, L., Dahl, M., Alfredsson, L. S., & Rane, A. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0048-2 · Cited by 84
Wrighton, S. A., & VandenBranden, M. R. (1989) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(89)90575-4 · Cited by 84
Knodell, R. G., Dubey, R. K., Wilkinson, G. R., et al. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24109-x · Cited by 82
Genetic polymorphism for human platelet thermostable phenol sulfotransferase (TS PST) activity.
Price, R. A., Spielman, R. S., Lucena, A. L., Loon, J. A. V., Maidak, B. L., & Weinshilboum, R. M. (1989) · Genetics · doi:10.1093/genetics/122.4.905 · Cited by 81
DeLozier, T. C., Lee, S. C., Coulter, S. J., Goh, B. C., & Goldstein, J. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.091181 · Cited by 79
McLeod, H. L., Fang, L., Luo, X., Scott, E. P., & Evans, W. E. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22361-8 · Cited by 78
Azathioprine in dermatology: a survey of current practice in the U.K.
Tan, B. B., Lear, J. T., Gawkrodger, D. J., & English, J. S. C. (1997) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1997.d01-1198.x · Cited by 77
Interethnic difference in omeprazole's inhibition of diazepam metabolism*
Caraco, Y., Tateishi, T., & Wood, A. J. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90073-x · Cited by 72
Self-citationPhenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo
Caraco, Y., Muszkat, M., & Wood, A. J. J. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00005 · Cited by 68
Self-citationDauvilliers, Y. A., Neidhart, E., Billiard, M. M., & Tafti, M. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500088 · Cited by 67
Correlation of erythrocyte catechol-O-methyltransferase activity between siblings
Weinshilboum, R. M., Raymond, F. A., Elveback, L. R., & Weidman, W. H. (1974) · Nature · doi:10.1038/252490a0 · Cited by 66
Grant, D. M., Blum, M., Demierre, A., & Meyer, U. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.10.3978 · Cited by 65
Smit, P., van Schaik, R. H. N., van der Werf, M., van den Beld, A. W., Koper, J. W., Lindemans, J. W., Pols, H. A. P., Brinkmann, A. O., de Jong, F. H., & Lamberts, S. W. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0307 · Cited by 65
Koukouritaki, S. B., & Hines, R. N. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.8.807 · Cited by 60
High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu
Kaneko, A., Kaneko, O., Taleo, G. K., Björkman, A., & Kobayakawa, T. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62696-7 · Cited by 59
Johnson, J., Nowacki, B., Turpie, A., & Ageno, W. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613932 · Cited by 58
Ishikawa, T., Tamura, A., Saito, H., Wakabayashi, K., & Nakagawa, H. (2005) · Die Naturwissenschaften · doi:10.1007/s00114-005-0019-4 · Cited by 57
Genetic diversity and function in the human cytosolic sulfotransferases
Hildebrandt, M. A. T., Carrington, D. P., Thomae, B. A., Eckloff, B. W., Schaid, D. J., Yee, V. C., Weinshilboum, R. M., & Wieben, E. D. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500404 · Cited by 56
Janicki, P. K., Schuler, H. G., Jarzembowski, T. M., et al. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000200364.55798.3f · Cited by 55
Skjelbo, E., Mutabingwa, T. K., Bygbjerg, I. C., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80008-7 · Cited by 54
Genetic Variants of the Human Dipeptide Transporter PEPT1
Anderle, P., Nielsen, C. U., Pinsonneault, J. K., Krog, P. L., Brodin, B., & Sadée, W. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094615 · Cited by 53
Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects
Liu, Z., Cheng, Z., Huang, S., Chen, X., Ouyang, D., Jiang, C., & Zhou, H. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01402.x · Cited by 53
Genomic organization of the UGT2b gene cluster on human chromosome 4q13
Riedy, M., Wang, J.-Y., Miller, A. P., Buckler, A., Hall, J., & Guida, M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200004000-00006 · Cited by 49
Morinobu, S., Tanaka, T., Kawakatsu, S., Totsuka, S., Koyama, E., CHIBA, K., Ishizaki, T., & Kubota, T. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02593.x · Cited by 45
Analyses of 5′ regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3)
Bhatnagar, V., Xu, G., Hamilton, B. A., Truong, D. M., Eraly, S. A., Wu, W., & Nigám, S. K. (2006) · Journal of Human Genetics · doi:10.1007/s10038-006-0398-1 · Cited by 45
Heterogeneity of paracetamol metabolism in Gilbert’s syndrome
Esteban, Á., & Pérez‐Mateo, M. (1999) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190005 · Cited by 41
Comparison of Human and Monkey Peptide Transporters: PEPT1 and PEPT2
Zhang, E. Y., Emerick, R. M., Pak, Y. A., Wrighton, S. A., & Hillgren, K. M. (2004) · Molecular Pharmaceutics · doi:10.1021/mp0499712 · Cited by 38
Recent advances in the pharmacogenomics of thiopurine methyltransferase
Coulthard, S., & Hall, A. G. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500066 · Cited by 37
Ieiri, I., Mamiya, K., Urae, A., et al. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00572.x · Cited by 33
Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
Daniel, H. I., & Ti, E. (1996) · PubMed · Cited by 30
Mephenytoin hydroxylation in the Cuna Amerindians of Panama.
Inaba, T., Jorge, L., & Arias, T. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03284.x · Cited by 29
Major Bleeding Caused by Warfarin in a Genetically Susceptible Patient
Bloch, A., Ben‐Chetrit, E., Muszkat, M., & Caraco, Y. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.1.97.33491 · Cited by 19
Self-citationJönsson, S., & Karlsson, M. O. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.02.004 · Cited by 18
Classification of Membrane Transporters
Sadée, W., Graul, R. C., & Lee, A. Y. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46812-3_2 · Cited by 10
Drug Transporters and Their Role in Tissue Distribution
Dantzig, A. H., Hillgren, K. M., & de Alwis, D. P. (2004) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(04)39021-4 · Cited by 7
Cited by
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Gage, B., Eby, C., Johnson, J., Deych, E., Rieder, M., Ridker, P., Milligan, P., Grice, G., Lenzini, P., Rettie, A., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.10 · Cited by 847
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., Stafberg, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311386 · Cited by 811
Metadata
- Authors
- Caraco, Y., Blotnick, S., & Muszkat, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-09-12
- Volume
- 83
- Issue
- 3
- Pages
- 460-470
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2032289591
- Cited by
- 360
- References
- 279
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.